Carregant...
Tipus de document
ArticleData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/174668
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.
Matèries
Matèries (anglès)
Citació
Citació
NADAL, Ernest, BOSCH BARRERA, Joaquim, CEDRÉS, S., COVES, J., GARCÍA CAMPELO, R., GUIRADO, M., LÓPEZ CASTRO, Rafael, ORTEGA, A. l., VICENTE, D., CASTRO CARPEÑO, Javier de. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). _Clinical and Translational Oncology_. 2021. Vol. 23, núm. 5, pàgs. 980-987. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/174668]